Affordable medicines and regulation of private hospitals

1. At a Glance

• Topic covers India's twin policy levers for healthcare cost containment: (a) price control of drugs via DPCO 2013 enforced by NPPA, and (b) regulation of private hospitals under the Clinical Establishments (Registration & Regulation) Act, 2010 [S1][S3].
• Sits at the intersection of Right to Health (Art. 21), federal division (Health = State subject), and Department of Pharmaceuticals (Min. of Chemicals & Fertilizers) stewardship [S1].
• Frequently tested in Prelims (NPPA, DPCO, Schedule-I, PMBJP) and Mains GS-II (health governance, vulnerable groups).

2. Why in the News

• PIB press release dated 17 March 2026 by Dept. of Pharmaceuticals reaffirmed the DPCO 2013 framework and NPPA's powers under Para 19 to fix prices in extraordinary circumstances / public interest [S1].
• Janaushadhi Saptah 2026 (March 2026); PMBJP crossed 18,646 Jan Aushadhi Kendras as of 28 Feb 2026 [S2].

3. Background & Evolution

• 1970: Drugs (Prices Control) Order first issued under Essential Commodities Act, 1955.
• 1997: NPPA established (29 Aug 1997) as attached office of Dept. of Pharmaceuticals.
• 2008: PMBJP launched (then "Jan Aushadhi Campaign") [S2].
• 2010: Clinical Establishments Act enacted by Parliament under Art. 252 (states' resolution) [S3].
• 2013: DPCO 2013 replaced DPCO 1995; shift from cost-based to market-based ceiling pricing linked to National List of Essential Medicines (NLEM) [S1].
• 2020 (11 Feb / w.e.f. 1 Apr 2020): Notified medical devices brought under DPCO 2013 [S3].

4. Core Static Facts

• Parent Ministry: Ministry of Chemicals & Fertilizers → Department of Pharmaceuticals [S1].
• Regulator: National Pharmaceutical Pricing Authority (NPPA) — sets ceiling prices of Schedule-I formulations and retail prices of "new drugs" [Para 2(1)(u) DPCO 2013] [S1].
• Non-scheduled drugs: MRP increase capped at 10% over preceding 12 months [S1].
• Para 19, DPCO 2013: Empowers NPPA to fix ceiling/retail prices in extraordinary circumstances & public interest [S1].
• Clinical Establishments Act, 2010: Currently in force in 10 States — Sikkim, Mizoram, Arunachal Pradesh, Himachal Pradesh, UP, Bihar, Jharkhand, Rajasthan, Uttarakhand, Assam — and all UTs except Delhi [S3].
• PMBJP: 18,646 Jan Aushadhi Kendras as of 28 Feb 2026; target 25,000 by March 2027 [S2].
• 10,000th JAK inaugurated at AIIMS Deoghar [S2].

5. Multi-Dimensional Analysis

Economic - Generic substitution via PMBJP reduces out-of-pocket (OOP) expenditure; medicines priced 50–90% below branded equivalents [S2]. - Price caps narrow pharma margins but expand volumes via universal coverage.

Legal / Constitutional - Health is a State subject (Entry 6, List II); CEA 2010 invoked Art. 252 so only consenting states are bound [S3]. - DPCO 2013 derives authority from Essential Commodities Act, 1955 (Concurrent List Entry 33) [S1].

Social - Affordable medicines critical for poor; 62%+ OOP share in India's health spending. - Private hospitals account for ~70% of outpatient and ~58% of inpatient care — regulatory gap hurts equity.

Administrative / Federal - Non-adoption of CEA by major states (Maharashtra, Karnataka, TN, Kerala, WB, Delhi) creates patchwork regulation [S3]. - NPPA's enforcement relies on State Drug Controllers — capacity bottleneck.

Ethical / Governance - Tension between innovation incentives (patents, TRIPS) and affordability (Section 3(d), Patents Act). - Overcharging by private hospitals during COVID-19 triggered Para 19 invocation on oximeters, masks, oxygen concentrators.

6. Recent Developments (last 12-18 months)

• 17 Mar 2026: PIB release reaffirms DPCO/NPPA framework [S1].
• Feb–Mar 2026: Janaushadhi Saptah & health camps across India [S2].
• Feb 2026: JAK count reaches 18,646; target 25,000 by Mar 2027 [S2].
• Medical devices regulated as "drugs" under DPCO since 1 Apr 2020 [S3].

7. Prelims Hooks

• DPCO 2013 issued under Essential Commodities Act, 1955 [S1].
• NPPA is under Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers (NOT Min. of Health) [S1].
• Schedule-I of DPCO 2013 lists formulations subject to ceiling price [S1].
• Para 19 = extraordinary public-interest pricing power of NPPA [S1].
• Non-scheduled drugs: MRP hike capped at 10% per year [S1].
• Clinical Establishments Act, 2010 enacted under Art. 252 [S3].
• CEA applies to 10 states + all UTs except Delhi [S3].
• PMBJP launched 2008; 18,646 JAKs by Feb 2026; target 25,000 by Mar 2027 [S2].
• 10,000th JAK opened at AIIMS Deoghar [S2].
• Medical devices notified as "drugs" w.e.f. 1 April 2020 [S3].
• Implementing agency for PMBJP: Pharmaceuticals & Medical Devices Bureau of India (PMBI).
• "New drug" defined in Para 2(1)(u) of DPCO 2013 [S1].

8. Mains Relevance

• GS-II: Government policies and interventions for development in social sectors (Health); issues relating to development and management of Social Sector/Services relating to Health.
• GS-III: Pharmaceutical sector / IPR.
• Probable stems: 1. "Price control alone cannot ensure access to affordable medicines in India. Examine the role of NPPA and PMBJP." 2. "The Clinical Establishments Act, 2010 has failed to achieve uniform regulation of private healthcare. Discuss the constitutional and administrative reasons." 3. "Discuss how the Drugs (Prices Control) Order, 2013 balances availability, affordability and innovation in India's pharmaceutical sector."

9. Related Topics to Study Next

• Ayushman Bharat – PM-JAY: insurance arm reducing OOP burden.
• National Health Policy 2017: target of 2.5% GDP public health spending.
• Patents Act 1970, Section 3(d) & compulsory licensing: Novartis vs UoI (2013).
• National Medical Commission Act, 2019: replaced MCI; regulates medical education.
• National List of Essential Medicines (NLEM 2022): feeder list for Schedule-I.
• Pradhan Mantri National Dialysis Programme & AMRIT pharmacies: parallel affordability schemes.
• TRIPS & Doha Declaration on Public Health.
• Right to Health Bill, Rajasthan 2023: first state statute.

10. Common Errors / Trap Areas

• NPPA is under Dept. of Pharmaceuticals, NOT Ministry of Health & Family Welfare [S1].
• DPCO is issued under Essential Commodities Act 1955, not Drugs & Cosmetics Act 1940.
• Clinical Establishments Act uses Art. 252 (not Art. 249 or 253); applies only to consenting states [S3].
• PMBJP implementing agency = PMBI (earlier BPPI), not NPPA.
• Schedule-I (DPCO) ≠ Schedule H/H1 (D&C Rules) — different lists, different purposes.

11. Sources

• [S1] Affordable medicines and regulation of private hospitals — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2241165 — (tier: 1)
• [S2] Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2236292 — (tier: 1)
• [S3] NPPA monitors prices of scheduled & non-scheduled medicines under DPCO 2013 / Medical Devices notified as Drugs — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2038955 ; https://www.pib.gov.in/PressReleaseIframePage.aspx?PRID=1609670 — (tier: 1)